Actively Recruiting
Randomized Study Comparing ORKA-002 to Placebo in Adults With Moderate-to-Severe Hidradenitis Suppurativa Evaluating Efficacy, Safety, and Pharmacokinetics
Led by Oruka Therapeutics, Inc. · Updated on 2026-10-29
200
Participants Needed
25
Research Sites
47 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ORKA-002, a drug administered by subcutaneous injection, in adult participants with moderate-to-severe Hidradenitis Suppurativa HS. This multicenter, randomized, double-blind, placebo-controlled study aims to assess the efficacy, safety, tolerability, and pharmacokinetics of ORKA-002 compared to placebo. The study is sponsored by Oruka Therapeutics, Inc. and involves participants who have had HS symptoms for at least 6 months with lesions in multiple areas and prior inadequate response or intolerance to systemic antibiotics. Participants will be randomly assigned to receive either ORKA-002 or placebo every 4 weeks during a 12-week double-blind induction period through Week 16. After this, all participants will enter an open-label maintenance period where ORKA-002 is given every 12 weeks. The study includes four distinct periods screening, induction double-blind, maintenance open-label, and post-treatment follow-up. During the study, participants will undergo regular assessments including the Hidradenitis Suppurativa Clinical Response HiSCR75 at Week 16, symptom diaries tracking worst skin pain, and safety monitoring through vital signs, laboratory tests, and electrocardiograms. The total study participation may extend through Week 92 for ongoing safety evaluations. Participants will also be monitored for adverse events throughout the study duration.
CONDITIONS
Brief Title
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
Research Team
O
Oruka Clinical Trials Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here